Review of chemopreventive strategies for familial adenomatous polyposis including NSAIDs and other agentsReview of chemoprevention options for familial adenomatous polyposis

This review examines various chemopreventive strategies for familial adenomatous polyposis. The scope includes nonsteroidal anti-inflammatory drugs, combination regimens, prostaglandin E2 receptor antagonists, phytoestrogens, targeted pathway inhibitors, gut microbiota modulation, and natural products. The authors synthesize current knowledge regarding these interventions without providing specific pooled effect sizes or adverse event rates. Key details regarding the study population, sample size, and setting were not reported in the source material.

The authors note that primary outcomes and secondary outcomes were not reported. Consequently, the review does not present definitive efficacy data or specific tolerability profiles. The absence of reported safety data limits the ability to assess risks associated with these chemopreventive approaches. The review highlights the need for further investigation to clarify the clinical utility of these strategies.

Practice relevance is constrained by the lack of quantitative evidence and the observational nature of the synthesis. Clinicians should interpret these findings with caution, recognizing that the review does not establish causal relationships or provide actionable dosing guidelines. The limitations of the available data prevent strong recommendations for routine use of these agents in this context.